12/03/2019 20:00:00

CLASS ACTION UPDATE for ARLO, TYME, KHC and SYNH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Arlo Technologies, Inc. (NYSE: ARLO)

Class Period: Investors who purchased shares pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the August 3, 2018 Initial Public Offering

Lead Plaintiff Deadline: March 25, 2019

Join the action: https://www.zlk.com/pslra-1/arlo-technologies-inc-loss-form?wire=3

The filed complaint alleges that the Registration Statement made materially false and/or misleading statements and/or failed to disclose that: (i) there was a flaw and/or quality issue with Arlo’s newly designed battery for its Ultra camera systems; (ii) this flaw and/or quality issue with the Ultra battery could result in a shipping delay of Arlo’s Ultra product; (iii) such a shipping delay endangered Arlo’s chances of launching the Ultra product in time for the crucial holiday season; (iv) such a shipping delay would allow Arlo’s competitors to capitalize on the Ultra product’s missed launch, thereby increasing their own market share; (v) Arlo’s consumers had been experiencing battery drain issues and other battery-related issues in connection with recent firmware updates; (vi) because of the foregoing, Arlo’s fourth quarter 2018 results and consumer base would be negatively impacted; and (vii) as a result, Arlo’s Registration Statement was materially false and misleading at all relevant times.

To learn more about the Arlo Technologies, Inc. class action contact jlevi@levikorsinsky.com.

Tyme Technologies, Inc. (NASDAQCM: TYME)

Class Period: March 14, 2018 - January 18, 2019

Lead Plaintiff Deadline: March 29, 2019

Join the action: https://www.zlk.com/pslra-1/tyme-technologies-inc-loss-form?wire=3

Allegations: Tyme Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (ii) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (iii) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (iv) as a result, Tyme’s public statements were materially false and misleading at all relevant times.

To learn more about the Tyme Technologies, Inc. class action contact jlevi@levikorsinsky.com.

The Kraft Heinz Company (NASDAQ: KHC)

Class Period: May 4, 2017 - February 21, 2019

Lead Plaintiff Deadline: April 25, 2019

Join the action: https://www.zlk.com/pslra-1/the-kraft-heinz-company-loss-form?wire=3

Allegations: During the class period, The Kraft Heinz Company made materially false and/or misleading statements and/or failed to disclose that: (a) Kraft Heinz had been materially overstating the value of certain of its important product lines; (b) Kraft Heinz’s intangible assets, including goodwill, associated with, at least, its Kraft natural cheese, Oscar Mayer cold cuts, U.S. Refrigerated and Canadian retail businesses were materially impaired; (c) Kraft Heinz had been employing improper accounting policies, procedures, and associated with its procurement function, including, but not limited to, agreements, side agreements, and changes or modifications to its agreements with its vendors; (d) Kraft Heinz had been improperly accounting for the costs of products sold; (e) Kraft Heinz had been operating with material weaknesses in its internal controls over financial reporting, including those controls related to the accounting and disclosure of new accounting standards, its cost of products sold, its procurement function, the impairment of goodwill and the impairment of intangible assets; (f) Kraft Heinz’s operating results were materially misstated and Defendants’ disclosures related thereto were materially false and misleading; (g) Kraft  Heinz’s  financial  statements  contained  material  errors,  were presented in violation of GAAP and were materially false and misleading; (h) the risk factor disclosures in filings Kraft Heinz made with the SEC were materially false and misleading; (i) the MD&A disclosures in filings Kraft Heinz made with the SEC were materially false and misleading; (j) the representations about Kraft Heinz’s disclosure controls and internal control over financial reporting in filings the Company made with the SEC were materially false and misleading; (k) the certifications issued by Defendants Hees, Basilio and Knopf on Kraft Heinz’s disclosure controls and internal controls over financial reporting were materially false and misleading; and (l) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about Kraft Heinz’s then-current business operations and future financial prospects.

To learn more about the The Kraft Heinz Company class action contact jlevi@levikorsinsky.com.

Syneos Health, Inc. (NASDAQ: SYNH)

Class Period: May 10, 2017 - February 27, 2019

Lead Plaintiff Deadline: April 30, 2019

Join the action: https://www.zlk.com/pslra-1/syneos-health-inc-loss-form?wire=3 

Allegations: Syneos Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Syneos Health’s internal control over financial reporting was inadequate; (2) concerns regarding Syneos Health’s internal control over financial reporting would result in heightened regulatory scrutiny and an SEC investigation into the company’s revenue accounting policies, internal controls and related matters; and (3) as a result, defendants’ statements about Syneos Health’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the Syneos Health, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com 

250x148_zlk.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 May
DANSKE
Meget interessant refleksion skrevet af Maui. Det kan vores medier godt lære lidt af. Det der kommer..
25
18 May
OMXC25
Et stort flertal af klimaforskerne mener klimaændringerne er menneskeskabte. Dvs. de uddannede perso..
22
15 May
PNDORA
I gaar aftes sad jeg og kiggede lidt naermere paa guidance fra Pandora for FY2019, som de meldte ud ..
22
14 May
E:THIN
Så sidder jeg her og glor på mit depot. Thinfilm falder ekstra meget i øjnene med afkast på minus 96..
20
18 May
VWS
Ditlev.. Havde store ambitioner, og store armbevægelser .. Ikke alt gik godt.. Men finanskrisen kan..
16
18 May
OMXC25
Når man begynder at bruge børn som Greta Thunberg for at fremhæve et budskab ringer advarselsklokker..
16
17 May
VELO
Hej Alle,   Har siddet og kigget på regnskabet, for at finde ud af hvordan 2019 ender. Umiddelbart e..
16
15 May
DANSKE
Apropos skribent 6212.. Og Danske Bank..Ja så må man lade vedkommende at han/hun fik ret. Han anbefa..
16
14 May
DANSKE
Sjovt at der ikke er nogen kritik af SKATs manglende kontrolindsats i forbindelse med momssvindlen, ..
16
18 May
ZEAL
Nedenfor er det samlet udskift af Q1 telefonkonferencen for Zealand Pharma.    Jeg har først trukket..
15

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
2
New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon® Blood Test
3
ESPERITE (ESP) announces listing measure by Euronext due to delay in publication of its 2018 annual report (as announced on 30 April 2019)
4
PRF: Consolidated Unaudited Interim Report of AS PRFoods for 3rd quarter and 9 months of 2018/2019 financial year
5
Eimskip: Letter from Gylfi Sigfússon´s attorney concerning District Prosecutor‘s investigation

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 May 2019 06:25:13
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190514.2 - EUROWEB7 - 2019-05-20 07:25:13 - 2019-05-20 06:25:13 - 1000 - Website: OKAY